Dronabinol - Vertanical GmbH
Alternative Names: delta-9-Tetrahydrocannabinol; VER-01Latest Information Update: 08 May 2025
At a glance
- Originator Vertanical
- Class Antidementias; Antiemetics; Antineoplastics; Appetite stimulants; Cannabinoids; Chromans; Muscle relaxants; Non-opioid analgesics; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Back pain
Most Recent Events
- 02 May 2025 Vertanical plans phase-III EXPAND trial for Back pain in November 2025 (PO), (NCT06956014)
- 18 Oct 2024 Vertanical completes the phase III ELEVATE trial in Back pain in Spain and Germany (PO, Solution) (NCT05610813) (EudraCT2022-001358-41)
- 30 Jun 2024 Vertanical GmbH plans the phase II RESPONSE trial Back pain (PO), in June 2024 (NCT06475001) (EudraCT2023-507358-34)